Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 60

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 3
Chunk 60
---
 may own or co-own intellectual property covering products that result from our collaboration with them, and in such cases, we would not have the exclusive right to develop or comm...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  disputes may arise with respect to the ownership of any intellectual property developed pursuant to our collaborations; and  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  a collaborator’s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Additionally, we may seek to enter into additional
collaborations, joint ventures, licenses and other similar arrangements for the development or commercialization of our product candidates,
due to capital costs required to develop or commercialize the product candidate or manufacturing constraints. We may not be successful
in our efforts to establish such collaborations for our product candidates because our research and development pipeline may be insufficient,
our product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view
our product candidates as having the requisite potential to demonstrate safety and efficacy or significant commercial opportunity. In
addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process can be time consuming
and complex. Further, any future collaboration agreements may restrict us from entering into additional agreements with potential collaborators.
We cannot be certain that, following a strategic transaction or license we will achieve an economic benefit that justifies such transaction.

Even if we are successful in our efforts to establish
such collaborations, the terms that we agree upon may not be favorable to us and we may not be able to maintain such collaborations if,
for example, development or approval of a product candidate is delayed, the safety of a product candidate is questioned or sales of an
approved product candidate are unsatisfactory.

In addition, any potential future collaborations
may be terminable by our strategic partners, and we may not be able to adequately protect our rights under these agreements. Furthermore,
strategic partners may negotiate for certain rights to control decisions regarding the development and commercialization of our product
candidates, if approved, and may not conduct those activities in the same manner as we do. Any termination of collaborations we enter
into in the future, or any delay in entering into